The Top 10 Pharmaceutical & Biotechnology R&D Investors



Pharma IQ
04/29/2014


Innovation is impossible without proper funding

Research based pharmaceutical companies are always striving to make advancements in science and technology, but this innovation comes at a price, R&D investment. Research and development of new therapies involves a complex, expensive, time-intensive and risky process. According to the Tufts Center for the Study of Drug Development, the cost of developing a new drug is at least $1.3 billion.

The Annual EU Industrial R&D Investment Scoreboard (the Scoreboard) contains economic and financial data for the world's top 2000 companies ranked by their investments in research and development (R&D). According to 2013 scoreboard pharmaceutical and biotechnology companies make up four of the world's top ten R&D investors: We take a closer look below at the Top 10 Pharmaceutical & Biotechnology R&D Investors in the world:
 

World - 2000 companies ranked by R&D World Rank  Name Country  R&D 2012 (€million) 

 R&D 1 year growth

(%)

 R&D 3 years growth (CAGR-3y, %) R&D intenstiy (%)                #6 Roche   Switzerland  7007.8  5.0  -3.8  18.6 #7 Novartis  Switerzland  6922.8  0.8  5.7  16.1 #8 Merck US  USA  5995.9  0.4  9.0  16.7 #9 Johnson & Johnson  USA  5809.5  1.6  1.6  11.4 #10 Pfizer  USA  5740.5  -14.0  -2.2  12.8 #15 Sanofi-aventis   France  4909.0  2.4  2.4  14.0 #20  GlaxoSmithKline  UK  4229.0  -3.5  -2.5  13.4 #26  Eli Lilly  USA  4000.4  5.1  5.3  23.4 #33  AstraZeneca  UK  3375.0  -5.6  5.2  15.9 #35  Abbott Laboratories  USA  3275.9  4.7  16.4  10.8